ADAM17 promotes glioma cell malignant phenotype

Molecular Carcinogenesis

Volumn 51, Issue 2, 2012, Pages 150-164

  Zheng, Xuguang ^a   Jiang, Feng ^a   Katakowski, Mark ^a   Lu, Yong ^a   Chopp, Michael ^a,b  

^a HENRY FORD HOSPITAL   (United States)

^b OAKLAND UNIVERSITY   (United States)

Author keywords

ADAM17; Angiogenesis; EGFR PI3K AKT; Glioma; Invasion; Proliferation; RNA interference; TACE; Tumor growth

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; EPIDERMAL GROWTH FACTOR RECEPTOR; METALLOPROTEINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SMALL INTERFERING RNA; TAPI 2; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ARTICLE; CANCER GROWTH; CANCER INVASION; CELL PROLIFERATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; GLIOMA; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR GROWTH; WESTERN BLOTTING;

ADAM PROTEINS; ANIMALS; BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; GLIOMA; HUMANS; MICE; MICE, NUDE; PHENOTYPE; RNA, MESSENGER; RNA, SMALL INTERFERING; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

MUS MUSCULUS;

EID: 84855225471     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20772     Document Type: Article

References (43)

1. Borrell-Pages M, Rojo F, Albanell J, Baselga J, Arribas J. TACE is required for the activation of the EGFR by TGF-alpha in tumors. EMBO J 2003; 22: 1114-1124.
2. Black RA. Tumor necrosis factor-alpha converting enzyme. Int J Biochem Cell Biol 2002; 34: 1-5.
3. Black RA, Rauch CT, Kozlosky CJ, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 1997; 385: 729-733.
4. Buxbaum JD, Liu KN, Luo Y, et al. Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor. J Biol Chem 1998; 273: 27765-27767.
5. Zatovicova M, Sedlakova O, Svastova E, et al. Ectodomain shedding of the hypoxia-induced carbonic anhydrase IX is a metalloprotease-dependent process regulated by TACE/ADAM17. Br J Cancer 2005; 93: 1267-1276.
6. Crowe PD, Walter BN, Mohler KM, Otten-Evans C, Black RA, Ware CF. A metalloprotease inhibitor blocks shedding of the 80-kD TNF receptor and TNF processing in T lymphocytes. J Exp Med 1995; 181: 1205-1210.
7. Mullberg J, Durie FH, Otten-Evans C, et al. A metalloprotease inhibitor blocks shedding of the IL-6 receptor and the p60 TNF receptor. J Immunol 1995; 155: 5198-5205.
8. Moss ML, Jin SL, Milla ME, et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature 1997; 385: 733-736.
9. Bennett TA, Lynam EB, Sklar LA, Rogelj S. Hydroxamate-based metalloprotease inhibitor blocks shedding of L-selectin adhesion molecule from leukocytes: Functional consequences for neutrophil aggregation. J Immunol 1996; 156: 3093-3097.
10. Katakowski M, Jiang F, Zheng X, Gutierrez JA, Szalad A, Chopp M. Tumorigenicity of cortical astrocyte cell line induced by the protease ADAM17. Cancer Sci 2009; 100: 1597-1604.
11. Murphy G. The ADAMs: Signalling scissors in the tumour microenvironment. Nat Rev Cancer 2008; 8: 932-941.
12. Zheng X, Jiang F, Katakowski M, et al. Inhibition of ADAM17 reduces hypoxia-induced brain tumor cell invasiveness. Cancer Sci 2007; 98: 674-684.
13. Zheng X, Jiang F, Katakowski M, Zhang ZG, Lu QE, Chopp M. ADAM17 promotes breast cancer cell malignant phenotype through EGFR-PI3K-AKT activation. Cancer Biol Ther 2009; 8: 1045-1054.
14. Blobel CP. ADAMs: Key components in EGFR signalling and development. Nat Rev Mol Cell Biol 2005; 6: 32-43.
15. Katakowski M, Chen J, Zhang ZG, Santra M, Wang Y, Chopp M. Stroke-induced subventricular zone proliferation is promoted by tumor necrosis factor-alpha-converting enzyme protease activity. J Cereb Blood Flow Metab 2007; 27: 669-678.
16. Mineo JF, Quintin-Roue I, Lucas B, Buburusan V, Besson G. Glioblastomas: Clinical study and search for prognostic factors. Neurochirurgie 2002; 48: 500-509.
17. Lee DC, Sunnarborg SW, Hinkle CL, et al. TACE/ADAM17 processing of EGFR ligands indicates a role as a physiological convertase. Ann NY Acad Sci 2003; 995: 22-38.
18. Fan H, Derynck R. Ectodomain shedding of TGF-alpha and other transmembrane proteins is induced by receptor tyrosine kinase activation and MAP kinase signaling cascades. EMBO J 1999; 18: 6962-6972.
19. Wells A. EGF receptor. Int J Biochem Cell Biol 1999; 31: 637-643.
20. Lal A, Glazer CA, Martinson HM, et al. Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion. Cancer Res 2002; 62: 3335-3339.
21. Datta SR, Brunet A, Greenberg ME. Cellular survival: A play in three Akts. Genes Dev 1999; 13: 2905-2927.
22. Maher EA, Furnari FB, Bachoo RM, et al. Malignant glioma: Genetics and biology of a grave matter. Genes Dev 2001; 15: 1311-1333.
23. Wechsler-Reya R, Scott MP. The developmental biology of brain tumors. Annu Rev Neurosci 2001; 24: 385-428.
24. Collins VP. Gene amplification in human gliomas. Glia 1995; 15: 289-296.
25. Schwechheimer K, Huang S, Cavenee WK. EGFR gene amplification-Rearrangement in human glioblastomas. Int J Cancer 1995; 62: 145-148.
26. Allinson TM, Parkin ET, Turner AJ, Hooper NM. ADAMs family members as amyloid precursor protein alpha-secretases. J Neurosci Res 2003; 74: 342-352.
27. Skinner HD, Zheng JZ, Fang J, Agani F, Jiang BH. Vascular endothelial growth factor transcriptional activation is mediated by hypoxia-inducible factor 1alpha, HDM2, and p70S6K1 in response to phosphatidylinositol 3-kinase/AKT signaling. J Biol Chem 2004; 279: 45643-45651.
28. Primakoff P, Myles DG. The ADAM gene family: Surface proteins with adhesion and protease activity. Trends Genet 2000; 16: 83-87.
29. He YY, Council SE, Feng L, Chignell CF. UVA-induced cell cycle progression is mediated by a disintegrin and metalloprotease/epidermal growth factor receptor/AKT/Cyclin D1 pathways in keratinocytes. Cancer Res 2008; 68: 3752-3758.
30. Zheng X, Jiang F, Katakowski M, et al. Sensitization of cerebral tissue in nude mice with photodynamic therapy induces ADAM17/TACE and promotes glioma cell invasion. Cancer Lett 2008; 265: 177-187.
31. Ding X, Yang LY, Huang GW, Wang W, Lu WQ. ADAM17 mRNA expression and pathological features of hepatocellular carcinoma. World J Gastroenterol 2004; 10: 2735-2739.
32. Jiang BH, Liu LZ. PI3K/PTEN signaling in tumorigenesis and angiogenesis. Biochim Biophys Acta 2008; 1784: 150-158.
33. Folkman J. Angiogenesis. Annu Rev Med 2006; 57: 1-18.
34. Xia C, Meng Q, Cao Z, Shi X, Jiang BH. Regulation of angiogenesis and tumor growth by p110 alpha and AKT1 via VEGF expression. J Cell Physiol 2006; 209: 56-66.
35. Jiang BH, Zheng JZ, Aoki M, Vogt PK. Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells. Proc Natl Acad Sci USA 2000; 97: 1749-1753.
36. Shand N, Weber F, Mariani L, et al. A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. GLI328 European-Canadian Study Group. Hum Gene Ther 1999; 10: 2325-2335.
37. Hart S, Fischer OM, Ullrich A. Cannabinoids induce cancer cell proliferation via tumor necrosis factor alpha-converting enzyme (TACE/ADAM17)-mediated transactivation of the epidermal growth factor receptor. Cancer Res 2004; 64: 1943-1950.
38. Ruhe JE, Streit S, Hart S, Ullrich A. EGFR signaling leads to downregulation of PTP-LAR via TACE-mediated proteolytic processing. Cell Signal 2006; 18: 1515-1527.
39. Ullrich A, Coussens L, Hayflick JS, et al. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 1984; 309: 418-425.
40. Kenny PA. Three-dimensional extracellular matrix culture models of EGFR signalling and drug response. Biochem Soc Trans 2007; 35: 665-668.
41. Kenny PA. TACE: A new target in epidermal growth factor receptor dependent tumors. Differentiation 2007; 75: 800-808.
42. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000; 19: 6550-6565.
43. Sahin U, Weskamp G, Kelly K, et al. Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands. J Cell Biol 2004; 164: 769-779.